Soft tissue and subcutaneous calcification in connective tissue diseases

Area of Science:

• Rheumatology
• Dermatology
• Immunology

Background:

• Calcinosis is a frequent manifestation in connective-tissue diseases, particularly juvenile dermatomyositis (JDM) and systemic sclerosis.
• The exact pathogenesis and effective treatments for calcinosis remain poorly understood.

Purpose of the Study:

• To review recent data on calcinosis in connective-tissue diseases.
• To emphasize the pathogenesis and treatment strategies for calcinosis.

Main Methods:

• Literature review of recently published data.
• Analysis of risk factors, pathogenetic mechanisms, and therapeutic approaches for calcinosis.

Main Results:

• Calcinosis is associated with sustained disease activity and longer disease duration.
• Specific genetic factors (e.g., TNFα-308AA allele) and antibodies (anti-p140) increase JDM calcinosis risk.
• Biomarkers like low fetuin-A, osteopontin, and elevated cytokines (IL-6, IL-1β, TNFα) are implicated in JDM calcinosis pathogenesis. Advanced glycation end products are noted in systemic sclerosis and lupus erythematosus with calcinosis.

Conclusions:

• No universally accepted standard therapy exists for calcinosis.
• Treatments targeting the underlying inflammatory condition, including IVIg, anti-TNF agents, thalidomide, and HSCT, have shown positive effects on calcinosis.
• While agents like warfarin, bisphosphonates, and diltiazem have been explored for direct calcinosis treatment with variable success, aggressive management of the primary disease is crucial.